AtheroNova, Inc.

Brooklyn, New York, Feb. 12, 2021 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the Thyroid Collar Shield Market will grow at a CAGR of 6.5 percent during the forecast period [2021 to 2026]. Thyroid, a butterfly shaped gland responsible for all the body’s metabolic process is at high risk of cancer due to radiation. Radiation-induced thyroid cancer has become a serious threat in the healthcare industry. Various government bodies including ATA have initiated a review to minimize these risks among the patient and healthcare provider. Dentistry and CT scans hold the most potential It is vital to wear the thyroid collar shield when undergoing for CT scan or dental x-ray due to their high radiation exposure. Rising number of tests pertaining to oral examination has positively influenced the adoption of protective clothing in the medical industry. CT scans pose a potential threat for thyroid cancer as they include high doses of radiation than a traditional x-ray. Also, the impact is highly dependent on co-factors such as age, health, and test type. Factors encouraging the mandatory use of these protective shields are associated with the routine dental check-up of children where radiology is required. Also, children have much more sensitive organs as compared to adults. Emergence of disposable thyroid collar shield Currently, the commercialized disposable protective shield meets all the standards imposed by the healthcare industry. These alternatives are more economical and can be disposed of easily without harming the environment. Rising awareness regarding more hygienic medical products along with problems faced by diagnostic centers to sterilize the re-usable shields will promote growth in this segment. Influenced from the covid-19 rules regarding the sanitization of medical equipment has encouraged the healthcare industry to use and promote one-time use of protective clothing specifically for the patients. It avoids unnecessary precautionary steps taken while dealing with different patients. Browse TOC on “Global Thyroid Collar Shield Market - Forecast to 2026" at Increase in the number of cases of thyroid cancer in North America The region has witnessed a significant number of people diagnosed with thyroid cancer. With the rising number of patients, the ATA has mandated the use of thyroid collar shields across all imaging testing. An increase in awareness among patients regarding radiation safety while undergoing the therapy or examination will drive the North American thyroid collar shield market growth. Companies focus on advanced material adoption and customize product type New material adoption along with product customization as per the customer regarding fit and closure type are key points of differentiation offered by the manufacturers. Shielding International, Protech Medical, Infab Corporation, Universal Medical, Mavig, Burkhart Roentgen International, Z&Z Medical, Kiran X-Ray, Trivitron Healthcare, Simad X-Ray Medical Technologies, and Bar Ray are few major industry players in the market. Thickness Outlook (Revenue, USD Million, 2019-2026) Less than 4 mm More than 4 mm Type Outlook (Revenue, USD Million, 2019-2026) Disposable Non-Disposable Application Outlook (Revenue, USD Million, 2019-2026) Dental X-Ray MRI CT Radiation & Mammography Procedure Laboratory Others Regional Outlook (Revenue, USD Million, 2019-2026) North America U.S. Canada Europe Germany UK France Italy Spain Russia Rest of Europe Asia Pacific China India Japan South Korea Australia Rest of Asia Pacific Latin America Brazil Argentina Mexico Rest of Latin America Middle East & Africa Saudi Arabia UAE South Africa Rest of the Middle East & Africa Request Free Sample Copy of the Report on “Global Thyroid Collar Shield Market - Forecast to 2026" at Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com Phone Number: + 1 602 666 7238 Website: Contact: Yash Jain Email address: yash.jain@globalmarketestimates.com Phone Number: + 1 602 666 7238

IRVINE, CA--(Marketwire - March 01, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, addressed a study presented at the American Stroke Association (ASA) conference that found a dramatic statistically significant increase in ischemic stroke hospitalizations among males and females in all age groups from 5 to 44 years old. "The research presented at the ASA conference demonstrates the drastic toll that atherosclerosis is taking among a significantly younger population group than was previously thought to be at such high risk from soft vulnerable plaque," stated Thomas W. Gardner, CEO of AtheroNova. "With our second round pre-clinical studies evaluating the atherosclerotic plaque regression efficacy of our compounds now in progress at two major research centers, this study adds to the body of clinical evidence demonstrating that atherosclerotic plaque is a huge and growing problem that must be addressed from early childhood onwards." "The evidence indicating that atherosclerosis is a lifelong problem only emphasizes the pressing need for the development of safe and effective treatments that can go beyond slowing the buildup of dangerous plaque deposits to actually demonstrate regression. Following the completion of our second round pre-clinical program expected within the next six months, we look forward to the filing of an Investigative New Drug application for our plaque regression compounds and the commencement of Phase I human trials," added Mr. Gardner. About AtheroNova AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis. Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the preclinical trials being conducted for the Company, the expected time to completion of the research and the ongoing development for AtheroNova's plaque regression compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Company Contact: Thomas Gardner Chief Executive Officer (949) 476-1100 Mark Selawski Chief Financial Officer (949) 476-1100 Investor Contact: Leon Hamerling Investor Media Group (877) 725-2500